Millions of people worldwide are affected by Parkinson's disease (PD), a common neurodegenerative disorder. This research focuses in order to increase the delivery of drugs to the brain and boost therapeutic effects, by the development of ropinirole-loaded chitosan nanoparticle in situ gels for intranasal administration.PD symptoms can be controlled with the help of the dopamine agonist ropinirole. For the Ropinirole loaded chitosan nanoparticles optimization, a Box-Behnken design (BBD) was used. As independent variables, chitosan, sodium tripolyphosphate (TPP), and ropinirole were used. Chitosan nanoparticles that have been loaded with ropinirole were assessed using the following criteria: particle size, PDI, drug entrapment effectiveness, and drug release kinetics. The formation of ropinirole-loaded chitosan nanoparticles with appropriate physicochemical properties was successful, according to the results. The FTIR study confirmed the drug-excipient compatibility. DSC examination revealed information about the thermal behavior of the nanoparticles. The formulated nanoparticles have the potential to improve intranasal delivery of drugs in the treatment of Parkinson's disease. Intranasal administration provides direct access to the central nervous system, avoiding the blood-brain barrier and decreasing systemic adverse effects. The nanoparticles showed prolonged drug release properties which can increase drug concentration in the brain while decreasing dose frequency.